Literature DB >> 8681611

Intrapleural fibrinolytics in management of empyema thoracis.

R T Temes1, F Follis, R M Kessler, S B Pett, J A Wernly.   

Abstract

STUDY
OBJECTIVE: To determine the success and complication rates of fibrinolytic therapy (FL) in the treatment of thoracic empyema. DESIGN AND PATIENTS: Between December 1992 and November 1994, all patients referred with empyema thoracis (ET) were offered FL. FL consisted of streptokinase (275,000 +/- 170,000 IU) or urokinase (121,000 +/- 57,000 IU) daily for a mean of 6.2 +/- 2.1 days.
SETTING: The University of New Mexico Health Sciences Center and the Albuquerque Veterans Affairs Medical Center.
RESULTS: Twenty-six patients were treated. Sixty-two percent (16/26) had complete resolution (CR) of symptoms, near or complete normalization of chest radiographic findings, and required no surgery or empyema tubes. Eight percent (2/26) had relief of symptoms and partial resolution (PR) of radiographic abnormalities and were discharged from the hospital with empyema tubes in place. All patients with PR had empyema tubes removed within 30 days of hospital discharge. Thirty-one percent (8/26) of patients failed to completely improve clinically or radiographically (nonresponse) and were treated with decortication or empyema tubes for greater than 30 days. Bleeding occurred in a single patient (4%). There was no mortality associated with FL use.
CONCLUSIONS: The use of FL is associated with resolution of ET in 69% (18/26) of patients. This modality is safe, effective, and spares most patients with empyema the morbidity and mortality of thoracotomy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8681611     DOI: 10.1378/chest.110.1.102

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  15 in total

1.  BTS guidelines for the management of pleural infection.

Authors:  C W H Davies; F V Gleeson; R J O Davies
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Emergent management of empyema.

Authors:  Osman Ahmed; Steven Zangan
Journal:  Semin Intervent Radiol       Date:  2012-09       Impact factor: 1.513

3.  Management of pleural effusion, empyema, and lung abscess.

Authors:  Hyeon Yu
Journal:  Semin Intervent Radiol       Date:  2011-03       Impact factor: 1.513

Review 4.  Use of fibrinolytic agents in the management of complicated parapneumonic effusions and empyemas.

Authors:  S A Sahn
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

5.  Cost-Effectiveness Analysis of Fibrinolysis versus Thoracoscopic Decortication for Early Empyema.

Authors:  Maren E Shipe; Amelia W Maiga; Stephen A Deppen; Diane N Haddad; Erin A Gillaspie; Fabien Maldonado; Benjamin D Kozower; Eric L Grogan
Journal:  Ann Thorac Surg       Date:  2020-11-27       Impact factor: 4.330

Review 6.  Surgical versus non-surgical management for pleural empyema.

Authors:  Mark D Redden; Tze Yang Chin; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2017-03-17

7.  Intrapleural fibrinolytic treatment of multiloculated pediatric empyemas.

Authors:  Refik Ulkü; Abdurrahman Onen; Serdar Onat; Nihal Kilinç; Cemal Ozçelik
Journal:  Pediatr Surg Int       Date:  2004-06-08       Impact factor: 1.827

8.  Empyema thoracis.

Authors:  A Balachandran; So Shivbalan; S Thangavelu; D Vijayasekaran; L Subramnayam
Journal:  Indian J Pediatr       Date:  2003-10       Impact factor: 1.967

9.  Percutaneous treatment of intrabdominal abscess: urokinase versus saline serum in 100 cases using two surgical scoring systems in a randomized trial.

Authors:  A Laborda; M A De Gregorio; J M Miguelena; J Medrano; J Gómez-Arrue; C Serrano; I de Blas; M Gimenez; H D'Agostino
Journal:  Eur Radiol       Date:  2009-02-04       Impact factor: 5.315

10.  Update on pleural diseases--2007.

Authors:  Ayman Bishay; Suhail Raoof; Adebayo Esan; Arthur Sung; Siraj Wali; Leonard Y Lee; Liziamma George; Anthony Saleh; Michael Baumann
Journal:  Ann Thorac Med       Date:  2007-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.